Novartis Hits Teva With Another Lotrel Suit

By Ben James (February 14, 2008, 12:00 AM EST) -- Novartis International AG now has two patent suits pending against generics maker Teva Pharmaceuticals USA Inc. over the blockbuster hypertension drug Lotrel, lodging a new complaint after Teva submitted a bid to make its proposed generic in different dosage strengths.

The Swiss drugmaker filed the latest Lotrel suit against Israeli generics maker Teva Pharmaceutical Industries Ltd's U.S. subsidiary on Feb. 7 in the U.S. District Court for the District of New Jersey.

The complaint notes that Novartis filed a suit against Teva USA in September 2004 involving the same patent but different dosage strengths.

Novartis learned in August 2004 that Teva...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!